# Kanjinti

NDC: 55513-132
Generic name: trastuzumab-anns
Labeler / Manufacturer: Amgen, Inc
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes: INTRAVENOUS
Marketing started: 20190611

FDA application: BLA761073

## Active ingredients

- TRASTUZUMAB: 420 mg/20mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"55513-132"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=55513-132
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9a94f5b2-b84e-4987-8ea1-c4346db5a5fa